Literature DB >> 6541207

Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs.

G A Ellard.   

Abstract

Mesh:

Substances:

Year:  1984        PMID: 6541207

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


× No keyword cloud information.
  5 in total

1.  Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

Review 2.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

3.  Structures, targets and recent approaches in anti-leishmanial drug discovery and development.

Authors:  Karin Seifert
Journal:  Open Med Chem J       Date:  2011-03-09

4.  Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.

Authors:  Rahul Shivahare; Preeti Vishwakarma; Naveen Parmar; Pawan Kumar Yadav; Wahajul Haq; Mrigank Srivastava; Suman Gupta; Susanta Kar
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

5.  qPCR-High resolution melt analysis for drug susceptibility testing of Mycobacterium leprae directly from clinical specimens of leprosy patients.

Authors:  Sergio Araujo; Luiz Ricardo Goulart; Richard W Truman; Isabela Maria B Goulart; Varalakshmi Vissa; Wei Li; Masanori Matsuoka; Philip Suffys; Amanda B Fontes; Patricia S Rosa; David M Scollard; Diana L Williams
Journal:  PLoS Negl Trop Dis       Date:  2017-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.